Quantcast

Planclear Study Highlights Positron’s 2010 Progress

December 2, 2010

PlanClear, the nuclear medicine industry’s premier Growth Management firm, has finalized and issued its performance report for the 2010 3rd Qtr and (partial) 4th Qtr accomplishments of industry leader Positron (POSC). The PlanClear report highlighted the accomplishment of three critical benchmarks: 1) Sale of 15 PET Camera systems within one year after receiving FDA approval, 2) Eliminating debt and strengthening the POSC balance sheet, and 3) Successful R&D efforts resulting in a new product launch that will automate SPECT dispensing process.

Herndon, VA (PRWEB) December 1, 2010

PlanClear, the nuclear medicine industry’s premier Growth Management firm, has finalized and issued its performance report for the 2010 3rd Qtr and (partial) 4th Qtr accomplishments of industry leader Positron (POSC).

The PlanClear report highlighted the accomplishment of three critical benchmarks:

1)    Sale of 15 PET Camera systems within one year after receiving FDA approval,

2)    Eliminating debt and strengthening the POSC balance sheet, and

3)    Successful R&D efforts resulting in a new product launch that will automate SPECT dispensing process.

“We wanted an independent study done by a company that truly understands the nuclear medicine field and the rapidly changing dynamics of the sector,” said Positron CEO Patrick Rooney, “and are thrilled to receive such a strong vote of confidence in our strategy – and results.”

PlanClear’s analysis shows the demand for PET cameras will continue to grow in the next ten years, with the dominant emerging design to be the PET-Only camera. PlanClear believes that although SPECT will gradually decline in the next decade, it will continue to play an important role in nuclear medicine. Specifically, the SPECT value chain will be altered via automation, with radiopharmaceutical intermediaries eliminated and direct customer access established between generator manufacturers and end users. PlanClear sees a strong future for Positron, as the company’s newly launched product will play a critical role in the SPECT value chain transformation.

PlanClear’s report confirms that Positron’s management is now taking the company in the right direction, with a leadership team providing the right balance between strategy and operating expertise. PlanClear does caution that execution and operating risks can impact future progress, and hence management would need a continuing and unwavering focus on operating excellence.

“PlanClear is impressed with the growth performance of the company ““ especially given that these results were achieved during extremely unfavorable economic conditions when healthcare spending had stagnated. We consequently see strong potential for the company,” said the PlanClear CEO Al Naqvi.

Report available for downloading at http://www.positron.com or http://www.planclear.com.

About Positron: a molecular imaging company focused on Nuclear Cardiology, Positron’s proprietary product line provides unique solutions to the Nuclear Medicine community, ranging from imaging to radiopharmaceutical distribution. Positron products include: the AttriusR, a PET imaging device; the PulseR, a SPECT imaging device; the Nuclear Pharm-AssistR, an automated radiopharmaceutical distribution device; and the Tech-AssistT, a radiopharmaceutical injection shield. More information is available at http://www.positron.com.

About PlanClear: a growth management firm that specializes in nuclear medicine industry, PlanClear enables companies to more quickly achieve sustainable and strong growth. The company offers the following services: strategic growth consulting, growth capital advisory, merger and acquisition strategy, new product success management, growth risk management and analysis, international growth management, and growth impact on stock value studies.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

For further information:

Al Naqvi

President and CEO, Plan Clear Company

Direct: 703-421-2229

or

Bob Marro

EVP, Plan Clear Company

Direct 703-421-8045

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2010/12/prweb4847744.htm


Source: prweb



comments powered by Disqus